1-Cyclopropyl-3-(4-sulfamoylphenyl)thiourea is a chemical compound with the molecular formula C10H13N3O2S2. It is not a well-known or extensively studied compound, and its importance in research is not readily available in public databases or scientific literature.
Here's why it might be difficult to find information about this specific compound:
* **Novelty:** It could be a newly synthesized compound or a derivative of a known compound with a specific modification.
* **Limited Research:** The research on this compound may be limited or confined to a specific area like pharmaceutical development or material science.
* **Specificity:** The compound might be involved in a niche research area or be a part of a specific patent or unpublished research project.
To understand the importance of 1-cyclopropyl-3-(4-sulfamoylphenyl)thiourea, you would need to investigate specific research papers or patents that mention this compound. You could try the following:
* **Search for the compound in scientific databases:** Use databases like PubChem, SciFinder, Reaxys, or Google Scholar to search for research papers or patents mentioning this compound.
* **Look for similar compounds:** Search for research on similar compounds with similar structures or functional groups. This could give you insights into the potential properties or applications of the target compound.
* **Contact experts:** Reach out to researchers in relevant fields (e.g., medicinal chemistry, organic chemistry, material science) who might be familiar with this compound or similar structures.
Remember that scientific research is a constantly evolving process, and new compounds and their applications are being explored regularly. Therefore, it's essential to stay updated with current research in your field of interest.
ID Source | ID |
---|---|
PubMed CID | 891589 |
CHEMBL ID | 1569076 |
CHEBI ID | 116191 |
Synonym |
---|
SDCCGMLS-0065250.P001 |
MLS000621401 |
smr000299501 |
4-{[(cyclopropylamino)carbonothioyl]amino}benzenesulfonamide |
CHEBI:116191 |
MLS-0065250.0002 |
AKOS003826816 |
MLS-0065250.0001 , |
1-cyclopropyl-3-(4-sulfamoylphenyl)thiourea |
HMS2694O10 |
CHEMBL1569076 |
bdbm46209 |
cid_891589 |
Q27198984 |
sr-01000263703 |
SR-01000263703-1 |
Class | Description |
---|---|
sulfonamide | An amide of a sulfonic acid RS(=O)2NR'2. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 19.9054 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 22.3872 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
phosphopantetheinyl transferase | Bacillus subtilis | Potency | 10.0000 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 3.1623 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 10.0000 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 23.7781 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 63.0957 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 23.9341 | 0.0601 | 10.7453 | 37.9330 | AID485367 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
dual specificity protein phosphatase 3 | Homo sapiens (human) | IC50 (µMol) | 54.2200 | 0.4000 | 9.3610 | 90.0000 | AID1957; AID1958; AID2684; AID449733 |
dual specificity protein phosphatase 6 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 99.5000 | 0.8320 | 24.1190 | 48.2000 | AID1055; AID2679 |
tyrosine-protein phosphatase non-receptor type 7 isoform 2 | Homo sapiens (human) | IC50 (µMol) | 35.6970 | 0.1000 | 12.7265 | 63.0000 | AID1077; AID2068; AID2678; AID449736 |
cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Rattus norvegicus (Norway rat) | IC50 (µMol) | 99.0000 | 0.0003 | 2.7232 | 10.0000 | AID1957 |
cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Rattus norvegicus (Norway rat) | IC50 (µMol) | 99.0000 | 0.0003 | 2.7232 | 10.0000 | AID1957 |
cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Rattus norvegicus (Norway rat) | IC50 (µMol) | 99.0000 | 0.0003 | 2.6638 | 10.0000 | AID1957 |
Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | IC50 (µMol) | 12.5000 | 0.0004 | 0.7649 | 12.5000 | AID1958 |
Amine oxidase [flavin-containing] A | Rattus norvegicus (Norway rat) | IC50 (µMol) | 12.5000 | 0.0007 | 1.9798 | 12.5000 | AID1958 |
cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Rattus norvegicus (Norway rat) | IC50 (µMol) | 99.0000 | 0.0003 | 2.7232 | 10.0000 | AID1957 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |